SCYNEXIS reports Phase 1 data show SCY-770 well tolerated in healthy adults for ADPKD program

Bitget2026/10/06 11:32

SCYNEXIS reported completed Phase 1 results for SCY-770, an oral AMPK activator in development for ADPKD. Results have already been presented, showing the drug was well tolerated with a favorable safety profile in healthy adults. Data supported dose selection work for a Phase 2 proof-of-concept trial, still targeted to start in Q4 2026. SCY-770 holds FDA orphan drug designation for ADPKD, positioning it as a potential first-in-class oral option. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060730PRIMZONEFULLFEED9840106) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.